h lundbeck as stroke drug is ineffective in late stage clinical trials danish pharmaceuticals company h lundbeck as said its experimental stroke drug desmoteplase worked no better than a placebo in late stage clinical trials the company said data from the phase iii trials arent consistent with previous findings and it will investigate expectations for the drug had been low because the sales potential was considered weak and the drug was deemed a high risk project but the setback following the discontinuation of potential insomnia drug gaboxadol in march will increase pressure on the company to find acquisitions analysts said lundbeck shares were down at kroner &# lundbeck licensed desmoteplase from german company paion ag in and holds marketing rights world wide except in the u s and canada 
